364 related articles for article (PubMed ID: 37489138)
1. Advances and Prospects in the Treatment of Pancreatic Cancer.
Duan H; Li L; He S
Int J Nanomedicine; 2023; 18():3973-3988. PubMed ID: 37489138
[TBL] [Abstract][Full Text] [Related]
2. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.
Sielaff CM; Mousa SA
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1205-1217. PubMed ID: 29721665
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
Song H; Jiang C
Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
Yang XY; Lu YF; Xu JX; Du YZ; Yu RS
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771172
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
[TBL] [Abstract][Full Text] [Related]
6. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
7. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
Wang Z; Wu B; Nie G; Wei J; Li Y
Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836
[TBL] [Abstract][Full Text] [Related]
8. The Emerging Landscapes to Drug Delivery Systems for the Treatment of Pancreatic Cancer.
Magri A; Baveloni FG; de Camargo BAF; Chorilli M
Curr Med Chem; 2021; 28(26):5411-5430. PubMed ID: 33745422
[TBL] [Abstract][Full Text] [Related]
9. Translational advances in pancreatic ductal adenocarcinoma therapy.
Hosein AN; Dougan SK; Aguirre AJ; Maitra A
Nat Cancer; 2022 Mar; 3(3):272-286. PubMed ID: 35352061
[TBL] [Abstract][Full Text] [Related]
10. Nonviral siRNA delivery systems for pancreatic cancer therapy.
Aghamiri S; Raee P; Talaei S; Mohammadi-Yeganeh S; Bayat S; Rezaee D; Ghavidel AA; Teymouri A; Roshanzamiri S; Farhadi S; Ghanbarian H
Biotechnol Bioeng; 2021 Oct; 118(10):3669-3690. PubMed ID: 34170520
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
12. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
13. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
14. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
17. Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine.
Ayasun R; Saridogan T; Gaber O; Sahin IH
Clin Colorectal Cancer; 2023 Mar; 22(1):2-11. PubMed ID: 36418197
[TBL] [Abstract][Full Text] [Related]
18. Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.
Zhu L; Mao H; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jul; 14(4):e1793. PubMed ID: 35396932
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
Diab M; Azmi A; Mohammad R; Philip PA
Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
[TBL] [Abstract][Full Text] [Related]
20. [Molecular targeted therapy strategy and clinical research progress in pancreatic ductal adenocarcinoma].
Yuan M; Sadulla A; Ren SQ; Yuan CH
Zhonghua Wai Ke Za Zhi; 2021 Nov; 59(11):956-960. PubMed ID: 34743461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
